Corticotropin-releasing factor (CRF) is a neurohormone that plays a crucial role in integrating the body’s overall
response to stress. It appears necessary and sufficient for the organism to mount functional, physiological and endocrine
responses to stressors. CRF is released in response to various triggers such as chronic stress. The role of CRF and its
involvement in these neurological disorders suggest that new drugs that can target the CRF function or bind to its receptors
may represent a new development of neuropsychiatric medicines to treat various stress-related disorders including
depression, anxiety and addictive disorders. Based on pharmacophore of the CRF1 receptor antagonists, a new series of
thiazolo[4,5-d] pyrimidines were synthesized as Corticotropin-releasing factor (CRF) receptor modulators and the prepared
compounds carry groups shown to produce optimum binding affinity to CRF receptors. Twenty two compounds
were evaluated for their CRF1 receptor binding affinity in HEK 293 cell lines and two compounds 5o and 5s showed approximately
25% binding affinity to CRF1 receptors. Selected compounds (5c and 5f) were also evaluated for their effect
on expression of genes associated with depression and anxiety disorders such as CRF1, CREB1, MAO-A, SERT, NPY,
DatSLC6a3, and DBH and significant upregulation of CRF1 mRNA has been observed with compound 5c.
Keywords: Thiazolo[4, 5-d]pyrimidines, corticotropin releasing factor, antalarmin, anxiety, depression.
Rights & PermissionsPrintExport